Disulfiram ameliorates bleomycin induced pulmonary inflammation and fibrosis in rats

References

• Ahadome SD, Abraham DJ, Rayapureddi S, Saw VP, Saban DR, Calder VL, Norman JT, Ponticos M, Daniels JT, Dart JK. 2016. Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring. JCI Insight. 1:e87001. doi: 10.1172/jci.insight.87001.
   PubMed Web of Science ®Google Scholar
• Altintas N, Erboga M, Aktas C, Bilir B, Aydin M, Sengul A, Ates Z, Topcu B, Gurel A. 2016. Protective effect of infliximab, a tumor necrosis factor-alfa inhibitor, on bleomycin-induced lung fibrosis in rats. Inflammation. 39:65–78. doi: 10.1007/s10753-015-0224-z.
   PubMed Web of Science ®Google Scholar
• Borthwick LA. 2016. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Sem Immunopathol. 38:517–534. doi: 10.1007/s00281-016-0559-z.
   PubMed Web of Science ®Google Scholar
• Brueckner B, Lyko F. 2004. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci. 25:551–554. doi: 10.1016/j.tips.2004.09.004.
   PubMed Web of Science ®Google Scholar
• Caduff N, McHugh D, Murer A, Rämer P, Raykova A, Landtwing V, Rieble L, Keller CW, Prummer M, Hoffmann L, Lam JKP, Chiang AKS, Raulf F, Azzi T, Berger C, Rubic-Schneider T, Traggiai E, Lünemann JD, Kammüller M, Münz C. 2020. Correction: immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog. 16:e1009167. doi: 10.1371/journal.ppat.1009167.
   PubMed Web of Science ®Google Scholar
• Christman JK. 2002. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 21:5483–5495. doi: 10.1038/sj.onc.1205699.
   PubMed Web of Science ®Google Scholar
• Cisneros J, Hagood J, Checa M, Ortiz-Quintero B, Negreros M, Herrera I, Ramos C, Pardo A, Selman M. 2012. Hypermethylation-mediated silencing of p14(ARF) in fibroblasts from idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 3034:295–303. doi: 10.1152/ajplung.00332.2011.
   Google Scholar
• Cvek B. 2011. Targeting malignancies with disulfiram (antabuse): multidrug resistance, angiogenesis, and proteasome. Curr Cancer Drug Targ. 11:332–337. doi: 10.2174/156800911794519806.
   PubMed Web of Science ®Google Scholar
• Dakhlallah D, Batte K, Wang Y, Cantemir-Stone CZ, Yan P, Nuovo G, Mikhail A, Hitchcock CL, Wright VP, Nana-Sinkam SP, Piper MG, Marsh CB. 2013. Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. Am J Resp Crit Care Med. 187:397–405. doi: 10.1164/rccm.201205-0888OC.
   PubMed Web of Science ®Google Scholar
• Dastjerdi MN, Babazadeh Z, Rabbani M, Gharagozloo M, Esmaeili A, Narimani M. 2014. Effects of disulfiram on apoptosis in PANC-1 human pancreatic cancer cell line. Res Pharmaceut Sci. 9:287–294.
   Google Scholar
• Dowson C, O’Reilly S. 2016. DNA methylation in fibrosis. Eur J Cell Biol. 95:323–330. doi: 10.1016/j.ejcb.2016.06.003.
   PubMed Web of Science ®Google Scholar
• Gailhouste L, Liew LC, Hatada I, Nakagama H, Ochiya T. 2018. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. Cell Death Disease. 9:468.
   PubMed Web of Science ®Google Scholar
• Grimaldi V, De Pascale MR, Zullo A, Soricelli A, Infante T, Mancini FP, Napoli C. 2017. Evidence of epigenetic tags in cardiac fibrosis. J Cardiol. 69:401–408. doi: 10.1016/j.jjcc.2016.10.004.
   PubMed Web of Science ®Google Scholar
• Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. 2002. Time course of bleomycin‐induced lung fibrosis. Int J Exp Pathol. 83:111–119.
   PubMed Web of Science ®Google Scholar
• Jiao YN, Hannafon B, Ding W-Q. 2016. Disulfiram’s anticancer activity: evidence and mechanisms. Anti-Cancer Agents Med Chem. 16:1378–1384. doi: 10.2174/1871520615666160504095040.
   PubMed Web of Science ®Google Scholar
• Kumar GL, Kiernan JA, editors. 2010. Education guide-special stains and H & E: pathology. Carpinteria (CA): Dako North America.
   Google Scholar
• Lee J-U, Son J-H, Shim E-Y, Cheong HS, Shin SW, Shin HD, Baek AR, Ryu S, Park CS, Chang HS. 2019. Global DNA methylation pattern of fibroblasts in idiopathic pulmonary fibrosis. DNA Cell Biol. 38:905–914. doi: 10.1089/dna.2018.4557.
   PubMed Web of Science ®Google Scholar
• Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, Kachhap SK, Shim JS, Liu JO, Nelson WG, Yegnasubramanian S, Carducci MA. 2011. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 71:333–343. doi: 10.1002/pros.21247.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu F, Kang L, Wang Z, Wang Y. 2017. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. BMC Pulmon Med. 17:1–11. doi: 10.1186/s12890-017-0405-7.
   PubMed Web of Science ®Google Scholar
• Liu P, Miao K, Zhang L, Mou Y, Xu Y, Xiong W, Yu J, Wang Y. 2020. Curdione ameliorates bleomycin-induced pulmonary fibrosis by repressing TGF-β-induced fibroblast to myofibroblast differentiation. Resp Res. 21:1–10. doi: 10.1186/s12931-020-1300-y.
   PubMed Web of Science ®Google Scholar
• Lyko F, Brown R. 2005. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 97:1498–1506. doi: 10.1093/jnci/dji311.
   PubMed Web of Science ®Google Scholar
• Mokhtari T, Hussein Osman HE, El-Meghawry El-Kenawy A, Dashti N. 2020. Ameliorative effect of virgin olive oil against nephrotoxicity following sub-chronic administration of ethephon in male rats. J Trad Comple Med. 10:487–495. doi: 10.1016/j.jtcme.2019.08.005.
   PubMedGoogle Scholar
• Neary R, Watson CJ, Baugh JA. 2015. Epigenetics and the overhealing wound: the role of DNA methylation in fibrosis. Fibrogen Tissue Rep. 8:18. doi: 10.1186/s13069-015-0035-8.
   PubMedGoogle Scholar
• Pourghasem M, Feizi F, Abedian Z, Ghasemi M, Babazadeh Z, Rabiee N. 2018. Time dependent of epigenetic effect of disulfiram on tumor suppressor gene of RASSF1A in HeLa cancer cell line. J Basic Res Med Sci. 5:8–13. doi: 10.29252/jbrms.5.2.8.
   Google Scholar
• Qiu L, Bi Y, Wang C, Li J, Guo P, Li J, He W, Wang J, Jiang P. 2014a. Protein a detection based on quantum dots-antibody bioprobe using fluorescence coupled capillary electrophoresis. Int J Mol Sci. 15:1804–1811. doi: 10.3390/ijms15021804.
   PubMed Web of Science ®Google Scholar
• Qiu X, Zhang L, Lu S, Song Y, Lao Y, Hu J, Fan H. 2014b. Upregulation of DNMT1 mediated by HBx suppresses RASSF1A expression independent of DNA methylation. Oncol Rep. 31:202–208. doi: 10.3892/or.2013.2848.
   PubMed Web of Science ®Google Scholar
• Robinson CM, Watson CJ, Baugh JA. 2012. Epigenetics within the matrix: a neo-regulator of fibrotic disease. Epigenetics. 7:987–993. doi: 10.4161/epi.21567.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Jono T, Fukuhara R, Boku S, Takebayashi M. 2021. Association between unknown long-term fever and depression in an adolescent patient. Psychiatry Clin Neurosci. 75:318–319.doi: 10.1111/pcn.13288.
   PubMed Web of Science ®Google Scholar
• Sharma V, Verma V, Lal N, Yadav SK, Sarkar S, Mandalapu D, Porwal K, Rawat T, Maikhuri JP, Rajender S, Sharma VL, Gupta G. 2016. Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor β. Mol Carcinogen. 55:1843–1857. doi: 10.1002/mc.22433.
   PubMed Web of Science ®Google Scholar
• Singh V, Sharma P, Capalash N. 2013. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targ. 13:379–399. doi: 10.2174/15680096113139990077.
   PubMed Web of Science ®Google Scholar
• Sonawane VK, Mahajan UB, Shinde SD, Chatterjee S, Chaudhari SS, Bhangale HA, Ojha S, Goyal SN, Kundu CN, Patil CR. 2018. A chemosensitizer drug: disulfiram prevents doxorubicin-induced cardiac dysfunction and oxidative stress in rats. Cardiovasc Toxicol. 18:459–470. doi: 10.1007/s12012-018-9458-y.
   PubMed Web of Science ®Google Scholar
• Tao H, Song ZY, Ding XS, Yang JJ, Shi KH, Li J. 2018. Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification. Heart Fail Rev. 23:789–799. doi: 10.1007/s10741-018-9694-z.
   PubMed Web of Science ®Google Scholar
• Tao H, Yang J-J, Chen Z-W, Xu S-S, Zhou X, Zhan HY, Shi KH. 2014. DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2. Toxicology. 323:42–50. doi: 10.1016/j.tox.2014.06.006.
   PubMed Web of Science ®Google Scholar
• Tao H, Yang JJ, Hu W, Shi KH, Li J. 2016. HDAC6 promotes cardiac fibrosis progression through suppressing RASSF1A expression. Cardiology. 133:18–26. doi: 10.1159/000438781.
   PubMed Web of Science ®Google Scholar
• Wickström M, Danielsson K, Rickardson L, Gullbo J, Nygren P, Isaksson A, Larsson R, Lövborg H. 2007. Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol. 73:25–33. doi: 10.1016/j.bcp.2006.08.016.
   PubMed Web of Science ®Google Scholar
• Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, Wynn TA. 2010. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med. 207:535–552. doi: 10.1084/jem.20092121.
   PubMed Web of Science ®Google Scholar
• Xin X, Yao D, Zhang K, Han S, Liu D, Wang H, Liu X, Li G, Huang J, Wang J. 2019. Protective effects of rosavin on bleomycin-induced pulmonary fibrosis via suppressing fibrotic and inflammatory signaling pathways in mice. Biomed Pharmacother. 115:108870. doi: 10.1016/j.biopha.2019.108870.
   PubMed Web of Science ®Google Scholar
• Yao HW, Li J. 2015. Epigenetic modifications in fibrotic diseases: implications for pathogenesis and pharmacological targets. J Pharmacol Exp Ther. 352:2–13. doi: 10.1124/jpet.114.219816.
   PubMed Web of Science ®Google Scholar
• Zekri A-R, Raafat AM, Elmasry S, Bahnassy AA, Saad Y, Dabaon HA, El-Kassas M, Shousha HI, Nassar AA, El-Dosouky MA. 2015. Promotor methylation: does it affect response to therapy in chronic hepatitis C (G4) or fibrosis? Ann Hepatol. 13:518–524. doi: 10.1016/S1665-2681(19)31251-7.
   Web of Science ®Google Scholar